Retail has time to accumulate whilst funds are closed or on holidays over the Christmas period. Corporate funds need to do hefty due diligence, report, get approval and then accumulate. This is a complex area with specialists needed to understand the significance of the results, to value the molecule per indication and to assess genuine comparable. For what it’s worth ImHO my research planning to hold for a comparable of minimum 1000% increase on current value for one molecule for one indication. There are currently three products for 3 specific indications and basket so a combined 8 +. The breast cancer results could take this into billion dollar territory, which management had pointed to in a number of presentations...
